JPH0360509B2 - - Google Patents
Info
- Publication number
- JPH0360509B2 JPH0360509B2 JP63320126A JP32012688A JPH0360509B2 JP H0360509 B2 JPH0360509 B2 JP H0360509B2 JP 63320126 A JP63320126 A JP 63320126A JP 32012688 A JP32012688 A JP 32012688A JP H0360509 B2 JPH0360509 B2 JP H0360509B2
- Authority
- JP
- Japan
- Prior art keywords
- cryoprecipitate
- blood
- plasma
- membrane
- anticoagulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002381 plasma Anatomy 0.000 claims description 90
- 210000004369 blood Anatomy 0.000 claims description 75
- 239000008280 blood Substances 0.000 claims description 75
- 239000012528 membrane Substances 0.000 claims description 47
- 210000003743 erythrocyte Anatomy 0.000 claims description 24
- 239000003146 anticoagulant agent Substances 0.000 claims description 22
- 229940127219 anticoagulant drug Drugs 0.000 claims description 22
- 239000012141 concentrate Substances 0.000 claims description 18
- 230000032258 transport Effects 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 16
- 238000000926 separation method Methods 0.000 claims description 14
- 239000011148 porous material Substances 0.000 claims description 12
- 210000000601 blood cell Anatomy 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 description 14
- 108010049003 Fibrinogen Proteins 0.000 description 14
- 229940012952 fibrinogen Drugs 0.000 description 14
- 239000003114 blood coagulation factor Substances 0.000 description 12
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 11
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 229940019700 blood coagulation factors Drugs 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920002284 Cellulose triacetate Polymers 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63320126A JPH0277265A (ja) | 1988-12-19 | 1988-12-19 | クリオプレシピテート分離装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63320126A JPH0277265A (ja) | 1988-12-19 | 1988-12-19 | クリオプレシピテート分離装置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59069531A Division JPS60214739A (ja) | 1984-04-06 | 1984-04-06 | クリオプレシピテート分離装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0277265A JPH0277265A (ja) | 1990-03-16 |
| JPH0360509B2 true JPH0360509B2 (cs) | 1991-09-13 |
Family
ID=18117991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63320126A Granted JPH0277265A (ja) | 1988-12-19 | 1988-12-19 | クリオプレシピテート分離装置 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0277265A (cs) |
-
1988
- 1988-12-19 JP JP63320126A patent/JPH0277265A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0277265A (ja) | 1990-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6527957B1 (en) | Methods for separating, collecting and storing red blood cells | |
| US4855063A (en) | Red blood cell filtering system | |
| US4713176A (en) | Plasmapheresis system and method | |
| Eriksson et al. | Platelet concentrates in an additive solution prepared from pooled buffy coats. In vitro studies | |
| US5234608A (en) | Systems and methods for processing cellular rich suspensions | |
| CN114748503B (zh) | 储存全血的方法及其组合物 | |
| US7182865B2 (en) | Device for separating whole blood under gravitational force | |
| EP0997158A2 (en) | Systems and methods for separating erythrocytes | |
| Lu et al. | Traditional and emerging technologies for washing and volume reducing blood products | |
| Boldt et al. | RETRACTED: Blood conservation in cardiac operations: Cell separation versus hemofiltration | |
| Hill et al. | Clinical prolonged extracorporeal circulation for respiratory insufficiency: hematological effects | |
| Gislason et al. | A treatment system for implementing an extracorporeal liver assist device | |
| Mayer et al. | Reduction of postoperative donor blood requirement by use of the cell separator | |
| JP4340927B2 (ja) | 赤血球組成物、および赤血球を収集しそして保存するための方法 | |
| US5217618A (en) | Plasma purification treatment | |
| Högman | Liquid‐Stored Red Blood Cells for Transfusion: A Status Report | |
| Weniger et al. | Reduction of bank blood requirements in cardiac surgery | |
| Lust et al. | In-line leukocyte filtration during bypass: clinical results from a randomized prospective trial | |
| JPH0360509B2 (cs) | ||
| Gulliksson et al. | A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with “split” apheresis platelets | |
| Högman et al. | Storage of red cells in a CPD/SAGM system using Teruflex® PVC | |
| JPH0359707B2 (cs) | ||
| Koster et al. | Autologous plasma and platelet sequestration at the beginning of cardiopulmonary bypass: a pilot investigation in five patients undergoing extended vascular surgery in deep hypothermia | |
| Lichtiger et al. | Hemotherapy during surgery for Jehovah's Witnesses: a new method | |
| Moskowitz et al. | Use of the Hemobag® for Modified Ultrafiltration in a Jehovah’s Witness Patient Undergoing Cardiac Surgery |